United States - English - NLM (National Library of Medicine)

cardinal health - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride is intended for short-term use. esmolol hydrochloride is indicated for the short-term treatment of tachycardia and/or hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride to prevent such events is not recommended. esmolol hydrochloride is contraindicated in patients with: pregnancy category c. esmolol hydrochloride has been shown to produce increa

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - supraventricular tachycardia esmolol hydrochloride is indicated for the rapid control of ventriculare rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated. intraoperative and postoperative tachycardia and/or hypertension esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on eemergence from anesthesia, and in the postoperative period, when in the physician's judgment such specific intervention is considered indicated. esmolol hydrochloride is contraindicated in patients with sinus bradycardia, heart block gre

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - supraventricular tachycardia esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short-term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated. intraoperative and postoperative tachycardia and/or hypertension esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician's judgment such specific intervention is considered indicated. use of esmolol to prevent such events is not recommended. esmolol hydrochloride is cont

United States - English - NLM (National Library of Medicine)

wg critical care, llc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride is intended for short-term use. esmolol hydrochloride is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride to prevent such events is not recommended. esmolol hydrochloride is contraindicated in patients with: pregnancy category c esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). there are no adequate and well-controlled studies in pregnant women. esmolol hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. in rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions. although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. esmolol hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from esmolol hydrochloride, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of esmolol hydrochloride in pediatric patients have not been established. clinical studies of esmolol hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy. no special precautions are necessary in patients with hepatic impairment because esmolol hydrochloride is metabolized by red-blood cell esterases [see clinical pharmacology (12.3) ]. no dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. there is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours [see clinical pharmacology (12.3) ].

United States - English - NLM (National Library of Medicine)

west ward pharmaceutical corporation - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride to prevent such events is not recommended. esmolol hydrochloride is contraindicated in patients with sinus bradycardia, heart block

United States - English - NLM (National Library of Medicine)

mylan institutional llc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride injection is intended for short-term use. esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride injection to prevent such events is not recommended. esmolol hydrochloride injection is contraindicated in patients with: esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). there are no adequate and well-controlled studies in pregnant women. esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. in rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions. although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from esmolol hydrochloride injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of esmolol hydrochloride injection in pediatric patients have not been established. clinical studies of esmolol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy. no special precautions are necessary in patients with hepatic impairment because esmolol hydrochloride injection is metabolized by red-blood cell esterases [see clinical pharmacology (12)] . no dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. there is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours [see clinical pharmacology (12)] .

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride injection is intended for short-term use. esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride injection to prevent such events is not recommended. esmolol hydrochloride injection is contraindicated in patients with: esmolol hydrochlori

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short-term control of ventricular rate with a short-acting agent is desirable.  esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention.  esmolol hydrochloride is intended for short-term use. esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride to prevent such events is not recommended. esmolol hydrochloride is contraindicated in patients with: - severe sinus bradycardia: may precipitate or

United States - English - NLM (National Library of Medicine)

eugia us llc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 100 mg in 10 ml - esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride injection is intended for short-term use. esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride injection to prevent such events is not recommended. esmolol hydrochloride injection is contraindicated in patients with: - severe sinus

United States - English - NLM (National Library of Medicine)

wg critical care, llc - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride in sodium chloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride in sodium chloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride in sodium chloride injection is intended for short-term use. esmolol hydrochloride in sodium chloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride in sodium chloride injection to prevent such events is not recomm